Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Flow diagram of the three-step incremental evaluation.

Abbreviations: AD: Alzheimer’s disease; CSF: cerebrospinal fluid; standard diagnostic program: medical history, physical and neurological examinations, cognitive testing, routine blood screening, and MRI; 2-[18F]FDG-PET: 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography;The stepwise diagnostic consensus evaluation was done by two blinded dementia specialists. In the first step, the evaluation was based solely on the standard diagnostic program. In the second step, the evaluation was based on the additional biomarker (CSF biomarkers or 2-[18F]FDG-PET). After 6 months, diagnostic consensus evaluation was done on the same patients in the stepwise process with addition of the other biomarker in the second step.

More »

Fig 1 Expand

Table 1.

Baseline demographics.

More »

Table 1 Expand

Table 2.

The clinical impact of 2-[18F]FDG-PET and CSF biomarkers on diagnosis and confidence in diagnosis.

More »

Table 2 Expand

Table 3.

The clinical impact of 2-[18F]FDG-PET and CSF biomarkers on disease course and confidence in disease course for patients with MCI and dementia.

More »

Table 3 Expand

Table 4.

Change in patient management following 2-[18F]FDG-PET and CSF.

More »

Table 4 Expand